Clinical TrialJul 17, 2026, 07:17 AM
Evaxion to Present 3-Year EVX-01 Phase 2 Data at ESMO Congress
AI Summary
Evaxion A/S will present three-year clinical efficacy data from its phase 2 trial of personalized cancer vaccine EVX-01 at the European Society for Medical Oncology (ESMO) Congress in October 2026. This data will offer insights into EVX-01's effect as a stand-alone therapy for advanced melanoma patients, potentially showing enhanced treatment effects and durability. Previous two-year data demonstrated a 75% Objective Response Rate and 92% durable response at two years, with no relapses observed.
Key Highlights
- Evaxion to present 3-year EVX-01 Phase 2 clinical data at ESMO Congress 2026.
- Data will include EVX-01 as stand-alone therapy for advanced melanoma patients.
- Previous 2-year data showed 75% Objective Response Rate (12 of 16 patients).
- 92% of patients were still responding at 2 years follow-up with no relapses.
- 54% of patients experienced a deepened response during treatment.
- EVX-01 induced immune response in all patients, with 86% T-cell responses.
- Global melanoma treatment market estimated to reach $7.4 billion by 2029.
Price Impact
More from EVAX